Rhumbline Advisers Dyne Therapeutics, Inc. Call Options Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
216Shares Held
116MCall Options Held
322KPut Options Held
66.2K-
Janus Henderson Group PLC London, X010.4MShares$122 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$114 Million2.11% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$107 Million27.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.41MShares$87.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$86.9 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $609M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...